The Conversation (0)
Reuters reports that melanoma patients treated with two Bristol-Myers Squibb drugs fared much better than those who received either of the medications individually, a new advance for treatments that harness the body’s immune system to fight cancer.
Reuters reports that melanoma patients treated with two Bristol-Myers Squibb drugs fared much better than those who received either of the medications individually, a new advance for treatments that harness the body’s immune system to fight cancer.
As quoted in the market news:
Bristol released preliminary data from the early-stage trial on Wednesday, with more detailed results expected to highlight the American Society of Clinical Oncology’s annual meeting in Chicago that starts at the end of the month.